Ebselen: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -130% 2 56 Improvement, Studies, Patients Relative Risk Mortality -130% 2 56 Recovery -17% 2 42 RCTs -130% 2 56 RCT mortality -130% 2 56 Late -130% 2 56 Ebselen for COVID-19 c19early.org July 2026 Favorsebselen Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -141% 2.41 [0.11-54.2] death 1/22 0/9 Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -125% 2.25 [0.29-17.2] death 4/16 1/9 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk All studies -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk 2 ebselen COVID-19 studies c19early.org July 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Effect extraction pre-specified(most serious outcome) Favors ebselen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -141% 2.41 [0.11-54.2] 1/22 0/9 Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -125% 2.25 [0.29-17.2] 4/16 1/9 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk All studies -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk 2 ebselen COVID-19 mortality results c19early.org July 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors ebselen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -21% 1.21 [0.53-2.76] no recov. 16 (n) 9 (n) Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -13% 1.13 [0.49-2.60] no recov. 11 (n) 6 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -17% 1.17 [0.65-2.10] 27 (n) 15 (n) 17% higher risk All studies -17% 1.17 [0.65-2.10] 27 (n) 15 (n) 17% higher risk 2 ebselen COVID-19 recovery results c19early.org July 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Favors ebselen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -141% 2.41 [0.11-54.2] death 1/22 0/9 Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -125% 2.25 [0.29-17.2] death 4/16 1/9 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk All studies -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk 2 ebselen COVID-19 Randomized Controlled Trials c19early.org July 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Effect extraction pre-specified(most serious outcome) Favors ebselen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -141% 2.41 [0.11-54.2] 1/22 0/9 Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -125% 2.25 [0.29-17.2] 4/16 1/9 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Late treatment -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk All studies -130% 2.30 [0.42-12.6] 5/38 1/18 130% higher risk 2 ebselen COVID-19 RCT mortality results c19early.org July 2026 Tau​2 = 0.00, I​2 = 0.0%, p = 0.34 Favors ebselen Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Treggiari (DB RCT) -141% 2.41 [0.11-54.2] death 1/22 0/9 Improvement, RR [CI] Treatment Control Treggiari (DB RCT) -21% 1.21 [0.53-2.76] no recov. 16 (n) 9 (n) Treggiari (DB RCT) -125% 2.25 [0.29-17.2] death 4/16 1/9 Treggiari (DB RCT) -13% 1.13 [0.49-2.60] no recov. 11 (n) 6 (n) Ebselen COVID-19 outcomes c19early.org July 2026 Favors ebselen Favors control